after gaining as much as 8.5% in New York on promising early-stage data. Those shares fell as Astra presented data on another pill that showed similar weight-loss benefits. Shares of obesity-shot ...

LONDON, United Kingdom - AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with ...

Data reported earlier Monday from Viking Therapeutics (NASDAQ:VKTX) on its weight loss medicine VK2735 indicates ... in both as an injectable and in pill form, is most closely related to Lilly's ...

LONDON, Nov 4 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, was safe and ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and competition between pharmaceutical rivals in the GLP-1 weight-loss drug space.

Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill. The San Diego-based company’s stock ...

Hence, we created a list of the best weight-loss pills guaranteed to work like magic and help you lose weight quickly. If you want to find the right fit, read this article till the end.

Viking Therapeutics stock soared 21% in early trade Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The study of VK2735 ...

Viking Therapeutics (VKTX) released new clinical trial data on Sunday for its experimental weight-loss drugs, which include a highly anticipated oral pill. The San Diego-based company’s stock surged ...

Oral GLP-1 drug in study led to average weight loss of 8.2% in a month at a 100 ... and is expected to launch a Phase 2 trial of the pill version by the end of the year. Details of study design ...

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy VK2735 exceeded expectations, with “class-leading” weight loss. Patients on ...